| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
October 25, 2022 |
|
|
| |
|
|
| |
|
|
|
Xtalks, online
2022 -12-08
The challenges of developing and validating qPCR assays in vaccine and therapeutic trials are manifold and hampered by a lack of harmonization of CRO’s.
The webinar will explore the advantages of qPCR in advancing life-enhancing therapeutics and why patients deserve the effort to harmonize. Validation performance characteristics are explored with a special focus on precision and sensitivity. Regarding precision, acceptable values for percent coefficient of variation is not clearly defined in the scientific literature or health agency publications. Uncertainty around precision is exacerbated by qPCR CV’s that are commonly higher than other traditional bioanalysis assays (e.g., ligand binding and chromatographic assays). Regarding sensitivity, the selection of PCR is based on its exceptional sensitivity (and specificity). Yet there is a lack of clarity around how to measure this and what the minimal requirements are.
The best practices and strategies for optimizing assays are discussed as is the importance of assay context of use in deciding acceptable precision and sensitivity. In-house summaries from analyses of more than 50 qPCR validations as well as experimental data comparing bead- vs column-based extraction will be presented. Finally, a case study is presented to link acceptable RT-qPCR validation performance with the efficacy of the Moderna Phase 3 COVID-19 vaccine.
Register for this webinar to learn the opportunities and challenges of developing and validating qPCR assays in vaccine and therapeutic trials.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Mark Wissel, PhD, Director of Research & Development, Eurofins Viracor Biopharma
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2022 -12-08
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|